Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Does Pfizer's Latest Biotech Move Make It a Buy?: https://g.foolcdn.com/editorial/images/741084/female-scientist-observing-with-microscope.jpg
Does Pfizer's Latest Biotech Move Make It a Buy?

On July 18, Pfizer (NYSE: PFE) announced that it is forging a strategic alliance with Flagship Pioneering, a venture capital (VC) firm, in which the pair would invest $50 million each into 10

2 Dirt Cheap Dividend Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/741024/patient-talking-with-a-physician.jpg
2 Dirt Cheap Dividend Stocks to Buy Right Now

Equity markets can be volatile, erratic, and not always entirely rational. That sometimes results in shares of companies not being adequately priced. And when these stocks trade for less than

2 Biotech Growth Stocks I'd Buy Right Now: https://g.foolcdn.com/editorial/images/740610/patient-sitting-on-hospital-bed.jpg
2 Biotech Growth Stocks I'd Buy Right Now

Since the beginning of 2023, equity markets have been experiencing what could be the start of a bull run. Buying shares of growth stocks is an excellent move for investors looking to ride this wave

AT&T Eats Verizon's Lunch: https://g.foolcdn.com/editorial/images/741319/gettyimages-1248402112.jpg
AT&T Eats Verizon's Lunch

Both AT&T (NYSE: T) and Verizon (NYSE: VZ) are dealing with consumers who have become less willing to upgrade their smartphones and more willing to switch wireless providers. For Verizon, this has

I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO: https://g.foolcdn.com/editorial/images/741243/gettyimages-968838136.jpg
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO

When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has

Does a Big Looming Liability for AT&T Put Its Dividend in Danger?: https://g.foolcdn.com/editorial/images/740659/telecom-worker-installing-5g-network.jpg
Does a Big Looming Liability for AT&T Put Its Dividend in Danger?

Telecom stocks are often reliable income investments to own, but investors aren't so sure that's the case with AT&T (NYSE: T). The stock yields 7.6% right now, as its share price has fallen 19% this

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Better Medtech Buy: J&J vs. Medtronic: https://g.foolcdn.com/editorial/images/741061/gettyimages-904880170.jpg
Better Medtech Buy: J&J vs. Medtronic

If you're shopping for a healthcare stock that promises growth, the medical technology space could offer some good choices. Many suffered at certain points during the earlier days of the pandemic as

EQS-News: Biotest AG: Biotest increases EBIT to Euro 19.8 million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest increases EBIT to Euro 19.8 million
EQS-News: Biotest AG: Biotest increases EBIT to Euro 19.8 million
EQS-News: Drägerwerk AG & Co. KGaA: Dräger with significant increase in net sales and earnings in the first half of 2023: https://assets2.sharewise.com/attachment/file/24054/375px-Dr%C3%A4ger_Logo.svg.png
EQS-News: Drägerwerk AG & Co. KGaA: Dräger with significant increase in net sales and earnings in the first half of 2023
EQS-News: Drägerwerk AG & Co. KGaA: Dräger with significant increase in net sales and earnings in the first half of 2023
Why Sage Therapeutics Stock Is Tumbling Today: https://g.foolcdn.com/editorial/images/741314/stock-crashing.jpg
Why Sage Therapeutics Stock Is Tumbling Today

Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of

AT&T; (T) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
AT&T; (T) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

AT&T (NYSE: T)Q2 2023 Earnings CallJul 26, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Like Growing Dividend Income? Buy This Dividend King: https://g.foolcdn.com/editorial/images/740788/a-pharmacist-serves-a-customer.jpg
Like Growing Dividend Income? Buy This Dividend King

Companies that possess the characteristic of consistency are arguably the foundation upon which all income portfolios should be built. That is because businesses that reliably grow over time can

2 Stocks That Raised Their Guidance in July: https://g.foolcdn.com/editorial/images/740653/investor-checking-stocks-on-his-phone.jpg
2 Stocks That Raised Their Guidance in July

One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ:

3 Stocks to Buy While They Are on Sale: https://g.foolcdn.com/editorial/images/740937/man-in-wheelchair-laptop.jpg
3 Stocks to Buy While They Are on Sale

There's one main downside to the tremendous performance of the stock market so far in 2023. Many stocks are now priced for perfection. And unfortunately, perfection is rarely attainable.

The good

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Down 97%, Is It Finally Time to Buy Invitae Stock?: https://g.foolcdn.com/editorial/images/740909/doctors-looking-at-tablet.jpg
Down 97%, Is It Finally Time to Buy Invitae Stock?

If you've only recently learned about Invitae (NYSE: NVTA), you can consider yourself lucky. A few years ago, the diagnostics business wowed Wall Street with plans to bring genetic testing to the

Why Biogen Stock Got Sick Today: https://g.foolcdn.com/editorial/images/741175/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg
Why Biogen Stock Got Sick Today

Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)

Biogen (BIIB) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Biogen (BIIB) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

2 Top Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/740455/physician-giving-medicine-to-elderly-patient.jpg
2 Top Dividend Stocks to Buy and Hold Forever

There are several reasons many investors gravitate toward dividend stocks. Some are attracted to the regular income stream, while others opt for dividend reinvestment to boost long-term returns

Should Growth Investors Buy This Revolutionary Small-Cap Stock?: https://g.foolcdn.com/editorial/images/740482/a-doctor-and-patient-at-an-appointment.jpg
Should Growth Investors Buy This Revolutionary Small-Cap Stock?

Achieving success as a growth investor revolves around picking companies that are taking new and potentially winning approaches to solving existing problems. These businesses can take their place as

Want to Build Wealth? Buy This Proven Healthcare Stock: https://g.foolcdn.com/editorial/images/740623/a-doctor-examines-a-patient-with-a-stethoscope.jpg
Want to Build Wealth? Buy This Proven Healthcare Stock

Since no two investors have the same plans and levels of risk tolerance, no two investment portfolios will be identical to each other. Although the goal for all investors is to build enough wealth

3 Red Flags for AT&T's Future: https://g.foolcdn.com/editorial/images/740710/att_retail_chicago.jpg
3 Red Flags for AT&T's Future

Over the past two years, AT&T (NYSE: T) tried to reset its business by selling its non-core assets and spinning off DirecTV and WarnerMedia. It claimed that a big reversal of its media expansion

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Will Qualcomm Be a Trillion-Dollar Stock by 2030?: https://g.foolcdn.com/editorial/images/740834/semiconductor-board.jpg
Will Qualcomm Be a Trillion-Dollar Stock by 2030?

Nvidia became the world's first trillion-dollar chipmaker this May, making it more than three times more valuable than Intel and Advanced Micro Devices combined. Nvidia's valuation skyrocketed to